phosphonoacetic acid has been researched along with Colorectal Cancer in 30 studies
Phosphonoacetic Acid: A simple organophosphorus compound that inhibits DNA polymerase, especially in viruses and is used as an antiviral agent.
phosphonoacetic acid : A member of the class of phosphonic acids that is phosphonic acid in which the hydrogen attached to the phosphorous is replaced by a carboxymethyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 9.10 | High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 9.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 9.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 8.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 7.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 7.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 5.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "The aim of this study was to investigate whether N-(phosphonacetyl)-L-aspartic acid (PALA) can enhance the activity of low-dose methotrexate (LD-MTX) modulated infusional 5-fluorouracil (5-FU) in patients with advanced colorectal cancer." | 5.10 | High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group. ( Baron, B; Bleiberg, H; Blijham, GH; Couvreur, ML; De Greve, J; Genicot, B; Jansen, RL; Kok, TC; Nortier, JW; Wagener, T; Wils, J, 2003) |
| "To report a new syndrome of ascites, hyperbilirubinemia, and hypoalbuminemia after treatment with N-phosphonacetyl-L-aspartate (PALA) and fluorouracil for metastatic colorectal cancer." | 5.07 | A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA) ( Costa, P; Kemeny, N; Kurtz, RC; Martin, D; Murray, M; Niedzwiecki, D; Seiter, K; Urmacher, C, 1991) |
| "A novel sequential administration schedule of PALA (N-phosphonoacetyl-L-aspartate) and thymidine to enhance the cytotoxic effect of 5-fluorouracil (5FU) was tested in 36 patients with advanced gastric cancer and 21 patients with advanced poorly differentiated (anaplastic) colorectal cancer." | 5.06 | A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer. ( Goldberg, RM; Krook, JE; Kugler, JW; Laurie, JA; Moertel, CG; O'Connell, MJ; Pfeifle, DM; Rubin, J; Wieand, HS; Windschitl, HE, 1990) |
| "5-Fluorouracil (5-FU) remains the agent of choice for the treatment of colorectal cancer." | 4.80 | Biomodulation of Fluorouracil in colorectal cancer. ( Ardalan, B; Franceschi, D; Jaime, M; Luis, R, 1998) |
| "For nearly four decades, 5-fluorouracil (5-FU) has been the mainstay of treatment for colorectal cancer." | 4.80 | Where do we stand with 5-fluorouracil? ( Büchele, T; Dempke, W; Grothey, A; Schmoll, HJ, 1999) |
| "5-Fluorouracil (5-FU) is still the mainstay of chemotherapy in patients with metastatic colorectal cancer." | 4.78 | Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials. ( Harstrick, A; Köhne-Wömpner, CH; Rustum, YM; Schmoll, HJ, 1992) |
| "The aim of this study was to investigate the utility of quantitating thymidylate synthase (TS) in the primary tumor as a surrogate for metastatic disease sites to predict the likelihood of response and outcome to fluorouracil (FU) treatment in patients with metastatic colorectal cancer." | 3.72 | Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites. ( Allegra, CJ; Benson, AB; Catalano, P; Johnston, PG; O'Dwyer, PJ; Rao, MS, 2003) |
| "Higher response rates in colorectal cancer have been observed with regimens that increase the cytotoxicity of fluorouracil (5-FU) by altering the biochemical milieu at its site(s) of action." | 3.68 | Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. ( Comis, RL; Litwin, S; O'Dwyer, PJ; Paul, AR; Walczak, J; Weiner, LM, 1990) |
| " Low dose and either continuous infusion or repetitive dosing of leucovorin, as well as the effect of treatment sequence and intervals between drugs, require additional investigation." | 2.39 | Preclinical and clinical aspects of biomodulation of 5-fluorouracil. ( Allegra, CJ; Grogan, L; Sotos, GA, 1994) |
| "The treatment of advanced colorectal cancer has improved in recent years." | 2.38 | Recent advances in the treatment of advanced colorectal cancer. ( Ahlgren, JD; Anderson, N; Kemeny, N; Lokich, JJ, 1993) |
| "The treatment of metastatic colorectal cancer by chemotherapy alone was considered palliative and without the potential to cure patients unless patients were rendered resectable." | 1.33 | Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases. ( Kemeny, NE; Leonard, GD, 2006) |
| "Twenty-one paired pharmacokinetic studies were completed on patients with colorectal, gastric, and hepatocellular cancer, utilizing positron emission tomography (PET), which allowed the acquisition of tumor, normal tissue, and plasma pharmacokinetic data and tumor blood flow (TBF) measurements." | 1.30 | Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa. ( Brady, F; Brown, G; Harte, RJ; Jones, T; Luthra, SJ; Matthews, JC; O'Reilly, SM; Osman, S; Price, PM; Tilsley, DW, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (3.33) | 18.7374 |
| 1990's | 24 (80.00) | 18.2507 |
| 2000's | 5 (16.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wils, J | 1 |
| Blijham, GH | 1 |
| Wagener, T | 1 |
| De Greve, J | 1 |
| Jansen, RL | 1 |
| Kok, TC | 1 |
| Nortier, JW | 1 |
| Bleiberg, H | 1 |
| Couvreur, ML | 1 |
| Genicot, B | 1 |
| Baron, B | 1 |
| Johnston, PG | 1 |
| Benson, AB | 2 |
| Catalano, P | 1 |
| Rao, MS | 1 |
| O'Dwyer, PJ | 7 |
| Allegra, CJ | 2 |
| Whitehead, RP | 1 |
| Benedetti, JK | 1 |
| Abbruzzese, JL | 1 |
| Ardalan, B | 3 |
| Williamson, S | 1 |
| Gaynor, ER | 1 |
| Balcerzak, SP | 1 |
| Macdonald, JS | 1 |
| Leonard, GD | 1 |
| Kemeny, NE | 1 |
| Sotos, GA | 1 |
| Grogan, L | 1 |
| Meropol, NJ | 1 |
| Creaven, PJ | 1 |
| Petrelli, NJ | 1 |
| Leichman, CG | 1 |
| Fleming, TR | 1 |
| Muggia, FM | 1 |
| Tangen, CM | 1 |
| Doroshow, JH | 1 |
| Meyers, FJ | 1 |
| Holcombe, RF | 1 |
| Weiss, GR | 1 |
| Mangalik, A | 1 |
| Cao, S | 1 |
| Rustum, YM | 2 |
| Spector, T | 1 |
| Kemeny, N | 4 |
| Lokich, JJ | 1 |
| Anderson, N | 1 |
| Ahlgren, JD | 1 |
| Weiner, LM | 3 |
| Hudes, GR | 2 |
| Kitson, J | 1 |
| Walczak, J | 2 |
| Watts, P | 1 |
| Litwin, S | 2 |
| Ragnhammar, P | 1 |
| Blomgren, H | 1 |
| Hageboutros, A | 1 |
| Greene, F | 1 |
| LaCreta, FP | 1 |
| Brennan, J | 1 |
| Köhne, CH | 2 |
| Wilke, H | 2 |
| Schöffski, P | 2 |
| Schmoll, HJ | 4 |
| Harstrick, A | 2 |
| Hiddemann, W | 1 |
| Bokemeyer, C | 1 |
| Dörken, B | 1 |
| Luis, R | 1 |
| Jaime, M | 1 |
| Franceschi, D | 1 |
| Soulie, P | 1 |
| Poupon, MF | 1 |
| Remvikos, Y | 1 |
| Dutrillaux, B | 1 |
| Muleris, M | 1 |
| Harte, RJ | 1 |
| Matthews, JC | 1 |
| O'Reilly, SM | 1 |
| Tilsley, DW | 1 |
| Osman, S | 1 |
| Brown, G | 1 |
| Luthra, SJ | 1 |
| Brady, F | 1 |
| Jones, T | 1 |
| Price, PM | 1 |
| Royce, ME | 1 |
| McGarry, W | 1 |
| Bready, B | 1 |
| Dakhil, SR | 1 |
| Belt, RJ | 1 |
| Goodwin, JW | 1 |
| Gray, R | 1 |
| Hoff, PM | 1 |
| Winn, R | 1 |
| Pazdur, R | 1 |
| Büchele, T | 1 |
| Grothey, A | 1 |
| Dempke, W | 1 |
| Manola, J | 1 |
| Valone, FH | 1 |
| Ryan, LM | 1 |
| Hines, JD | 1 |
| Wadler, S | 1 |
| Haller, DG | 1 |
| Arbuck, SG | 1 |
| Mayer, RJ | 1 |
| Köhne-Wömpner, CH | 1 |
| Fowler, WC | 1 |
| Eisenberg, BL | 1 |
| Hoffman, JP | 1 |
| Conti, JA | 1 |
| Seiter, K | 2 |
| Niedzwiecki, D | 2 |
| Botet, J | 1 |
| Martin, D | 2 |
| Costa, P | 2 |
| Wiseberg, J | 1 |
| McCulloch, W | 1 |
| Urmacher, C | 1 |
| Kurtz, RC | 1 |
| Murray, M | 1 |
| Cheson, BD | 1 |
| Windschitl, HE | 1 |
| O'Connell, MJ | 1 |
| Wieand, HS | 1 |
| Krook, JE | 1 |
| Rubin, J | 1 |
| Moertel, CG | 1 |
| Kugler, JW | 1 |
| Pfeifle, DM | 1 |
| Goldberg, RM | 1 |
| Laurie, JA | 1 |
| Paul, AR | 1 |
| Comis, RL | 1 |
| Schneider, A | 1 |
| Martin, DS | 1 |
| Colofiore, J | 1 |
| Sawyer, RC | 1 |
| Derby, S | 1 |
| Salvia, B | 1 |
9 reviews available for phosphonoacetic acid and Colorectal Cancer
| Article | Year |
|---|---|
Preclinical and clinical aspects of biomodulation of 5-fluorouracil.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neopla | 1994 |
Biochemical modulation as an approach to reversal of antimetabolite resistance.
Topics: Antimetabolites, Antineoplastic; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug | 1994 |
Metastatic colorectal cancer: advances in biochemical modulation and new drug development.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisplatin; Colorectal Neoplasms; Diar | 1995 |
Recent advances in the treatment of advanced colorectal cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Drug Administra | 1993 |
How to optimize the effect of 5-fluorouracil modulated therapy in advanced colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Asp | 1995 |
The dead end of 5-fluorouracil double modulation and promise of continuous infusion schedules in the treatment of metastatic colorectal cancer.
Topics: Adenocarcinoma; Antimetabolites, Antineoplastic; Aspartate Carbamoyltransferase; Aspartic Acid; Clin | 1996 |
Biomodulation of Fluorouracil in colorectal cancer.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clin | 1998 |
Where do we stand with 5-fluorouracil?
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Chro | 1999 |
Chemotherapeutic strategies in metastatic colorectal cancer: an overview of current clinical trials.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Cisp | 1992 |
9 trials available for phosphonoacetic acid and Colorectal Cancer
| Article | Year |
|---|---|
High-dose 5-fluorouracil plus low dose methotrexate plus or minus low-dose PALA in advanced colorectal cancer: a randomised phase II-III trial of the EORTC Gastrointestinal Group.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Di | 2003 |
A phase II pilot study of high-dose 24-hour continuous infusion of 5-FU and leucovorin and low-dose PALA for patients with colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Do | 2004 |
Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.
Topics: Adult; Aged; Aged, 80 and over; Agranulocytosis; Antineoplastic Agents; Antineoplastic Combined Chem | 1995 |
Phase I trial of fluorouracil modulation by N-phosphonacetyl-L-aspartate and 6-methylmercaptopurine ribonucleoside (MMPR), and leucovorin in patients with advanced cancer.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Aspartic Acid; Colorectal Neoplasms; Drug Interactions | 1997 |
Modulation of 5-fluorouracil with methotrexate and low-dose N-(phosphonacetyl)-L-aspartate in patients with advanced colorectal cancer. Results of a phase II study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; Fe | 1997 |
Sequential biochemical modulation of fluorouracil with folinic acid, N-phosphonacetyl-L-aspartic acid, and interferon alfa-2a in advanced colorectal cancer.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Antineoplastic Agents; Aspartic Aci | 1999 |
Fluorouracil modulation in colorectal cancer: lack of improvement with N -phosphonoacetyl- l -aspartic acid or oral leucovorin or interferon, but enhanced therapeutic index with weekly 24-hour infusion schedule--an Eastern Cooperative Oncology Group/Cance
Topics: Administration, Oral; Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluo | 2001 |
A new syndrome: ascites, hyperbilirubinemia, and hypoalbuminemia after biochemical modulation of fluorouracil with N-phosphonacetyl-L-aspartate (PALA)
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Ascites; Aspartic Acid; Colorectal Neoplasms; | 1991 |
A clinical trial of biochemical modulation of 5-fluorouracil with N-phosphonoacetyl-L-aspartate and thymidine in advanced gastric and anaplastic colorectal cancer.
Topics: Adult; Aged; Aspartic Acid; Clinical Trials as Topic; Colorectal Neoplasms; Drug Evaluation; Drug Sy | 1990 |
12 other studies available for phosphonoacetic acid and Colorectal Cancer
| Article | Year |
|---|---|
Thymidylate synthase protein expression in primary colorectal cancer: lack of correlation with outcome and response to fluorouracil in metastatic disease sites.
Topics: Adenocarcinoma; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocol | 2003 |
Continued survival of more than ten years, without resection of metastatic disease, in patients with metastatic colorectal cancer treated with biomodulated fluorouracil: report of two cases.
Topics: Acetates; Aged; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colorectal Neoplasms; | 2006 |
5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing advanced colorectal carcinoma.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic A | 1994 |
Preservation of immune effector cell function following administration of a dose-intense 5-fluorouracil-chemotherapy regimen.
Topics: Adenocarcinoma; Antibody-Dependent Cell Cytotoxicity; Antineoplastic Combined Chemotherapy Protocols | 1993 |
Distinct chromosomal alterations associated with TP53 status of LoVo cells under PALA selective pressure: a parallel with cytogenetic pathways of colorectal cancers.
Topics: Aspartic Acid; Chromosome Aberrations; Colorectal Neoplasms; Drug Resistance; Enzyme Inhibitors; Gen | 1999 |
Tumor, normal tissue, and plasma pharmacokinetic studies of fluorouracil biomodulation with N-phosphonacetyl-L-aspartate, folinic acid, and interferon alfa.
Topics: Adult; Aged; Aged, 80 and over; Antimetabolites, Antineoplastic; Area Under Curve; Aspartic Acid; Co | 1999 |
Hepatic resection following systemic chemotherapy for metastatic colorectal carcinoma.
Topics: Aged; Antineoplastic Agents; Aspartic Acid; Colorectal Neoplasms; Female; Fluorouracil; Hepatectomy; | 1992 |
Biochemical modulation of bolus fluorouracil by PALA in patients with advanced colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy P | 1992 |
Clinical trials referral resource. Treatment of advanced colorectal cancer.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Clinical Trial | 1991 |
Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer.
Topics: Adenocarcinoma; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Aspa | 1990 |
Biochemical modulation of 5-fluorouracil by PALA.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid; Colo | 1990 |
Phase I trial of N-(phosphonacetyl)-L-aspartate, methotrexate, and 5-fluorouracil with leucovorin rescue in patients with advanced cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aspartic Acid | 1989 |